Verucerfont

Non Chimik:

(S)-3-(4-methoxy-2-methylphenyl)-2,5-dimethyl-N-(1-(3-methyl-1,2,4-oxadiazol-5-yl)propyl)pyrazolo[1, 5-a] pirimidin-7-amine

Kòd SMILES:

CC[C@H](NC1=CC(C)=NC2=C(C3=CC=C(OC)C=C3C)C(C)=NN12)C4=NC(C)=NO4

Kòd InChi:

InChI=1S/C22H26N6O2/c1-7-18(22-24-15(5)27-30-22)25-19-11-13(3)23-21-20(14) (4)26-28(19)21)17-9-8-16(29-6)10-12(17)2/h8-11,18,25H,7H2,1-6H3/t18-/m0/ s1

InChi kle:

VKHVAUKFLBBZFJ-SFHVURJKSA-N

Mot:

Verucerfont, GSK561679, GSK 561679, GSK-561679, NBI77860, NBI 77860, NBI-77860, 885220-61-1

Solibilite:Soluble nan DMSO

Depo:0 - 4 ° C pou kout tèm (jou a semèn), oswa -20 ° C pou tèm long (mwa).

Deskripsyon:

"Verucerfont, ke yo rele tou GSK561679 ak NBI77860, se yon antagonist CRF-1. Verucerfont bloke reseptè CRH-1 a, epi konsa diminye lage ACTH apre estrès kwonik. Li anba envestigasyon kòm yon tretman potansyèl pou alkòl, kòm estrès kwonik souvan se. yon faktè nan tou de devlopman nan alkòl ak rplonje nan rekipere alkòl Li te montre rezilta pwomèt nan syans sou bèt men li pa gen te teste sou moun."

Sib: CRF-1